Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evolitizumab
- Development stage
- Unknown
- Lead developer
- Himalaya Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HTBA3071 (evolitizumab) is a conditionally active monoclonal antibody targeting Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), an immune checkpoint receptor. Developed by Himalaya Therapeutics using the Conditionally Active Biologics (CAB) technology platform, the antibody is engineered to bind its target preferentially in the unique microenvironment of tumors (such as low pH), which is intended to improve the safety profile by reducing systemic immune-related adverse events. By blocking the interaction between CTLA-4 and its ligands (CD80/CD86), evolitizumab enhances anti-tumor T-cell activation and proliferation. It is currently in Phase 1/2 clinical development for the treatment of various solid tumors, including melanoma and non-small cell lung cancer (NSCLC).
- Other names
- evolitizumabCAB-CTLA-4CAB-CTLA4CAB-CTLA 4
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on evolitizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evolitizumab.